Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Authors :: Tracey Rowlands
I. Lowy
Lee S. Rosen
P. Lopez Criado
M. Feng
M. Gil-Martin
Elizabeth Stankevich
Melissa Lynne Johnson
P. Rietschel
Kosalai Kal Mohan
V. Moreno
Donald W. Northfelt
P. Garrido Lopez
Jingjin Li
Raid Aljumaily
Marka R. Crittenden
Matthew G. Fury
Salma K. Jabbour
A. Hervás Morón
Source :: Web of Science
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: business.industry
medicine.medical_treatment
Anti pd 1
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
030226 pharmacology & pharmacy
Radiation therapy
03 medical and health sciences
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cohort
Monoclonal
medicine
Cancer research
business

Tools